2009
DOI: 10.1590/s0100-72032009000100005
|View full text |Cite
|
Sign up to set email alerts
|

Exenteração pélvica para câncer do colo uterino recidivado pós-radioterapia: experiência de um centro terciário do Nordeste brasileiro

Abstract: PURPOSE: to analyze complications, morbidity, mortality and survival rate in a group of patients with cervical cancer with central pelvic relapse after primary radiotherapy treatment. METHODS: retrospective study of a series of 16 cases of pelvic exenteration after primary radiotherapy treatment. Descriptive statistics, survival curve through Kaplan-Meier's method, and regression analysis to evaluate prognosis were performed. RESULTS: sixteen patients have undergone pelvic exenteration. Epidermoid carcinoma, I… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2011
2011
2013
2013

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 5 publications
0
4
0
Order By: Relevance
“…The best-quality RCT found compared cisplatin with no cisplatin with both groups receiving radiotherapy, 127 which gave an overall 5-year survival with cisplatin of 63% and without cisplatin of 59%. Only case series were found on radiotherapy (nine studies [84][85][86][87][88][89][90][91][92] ), chemoradiotherapy (seven studies [93][94][95][96][97][98][99] ), radical hysterectomy (seven studies [100][101][102][103][104][105][106] ) and pelvic exenteration (20 studies [107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126] ). The survival rates varied considerably, depending on the date of publication, characteristics of patients and type of treatment given.…”
Section: Effectiveness Reviewmentioning
confidence: 99%
“…The best-quality RCT found compared cisplatin with no cisplatin with both groups receiving radiotherapy, 127 which gave an overall 5-year survival with cisplatin of 63% and without cisplatin of 59%. Only case series were found on radiotherapy (nine studies [84][85][86][87][88][89][90][91][92] ), chemoradiotherapy (seven studies [93][94][95][96][97][98][99] ), radical hysterectomy (seven studies [100][101][102][103][104][105][106] ) and pelvic exenteration (20 studies [107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126] ). The survival rates varied considerably, depending on the date of publication, characteristics of patients and type of treatment given.…”
Section: Effectiveness Reviewmentioning
confidence: 99%
“…Twenty case series, [107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126] published between 1953 and 2009, presented results on pelvic exenteration, mostly from the USA (Table 49). The number of patients varied between 14 and 263.…”
Section: Pelvic Exenteration Population Characteristicsmentioning
confidence: 99%
“…The best-quality RCT found compared cisplatin with no cisplatin with both groups receiving radiotherapy, 127 which gave an overall 5-year survival with cisplatin of 63% and without cisplatin of 59%. Only case series were found on radiotherapy (nine studies [84][85][86][87][88][89][90][91][92] ), chemoradiotherapy (seven studies [93][94][95][96][97][98][99] ), radical hysterectomy (seven studies [100][101][102][103][104][105][106] ) and pelvic exenteration (20 studies [107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124][125][126] ). The survival rates varied considerably, depending on the date of publication, characteristics of patients and type of treatment given.…”
Section: Effectiveness Reviewmentioning
confidence: 99%
“…The rate of women who had received chemotherapy was 62.6% (4) ; that of those who underwent brachytherapy, 65.3% (5) ; and that of those who underwent pelvic exenteration after primary radiotherapy treatment, 64.3% (6) . Probably, these differences are more closely associated with the extent of the disease, which determines the type of treatment.…”
Section: Introductionmentioning
confidence: 99%